Symbol
| TMPRSS2
| contributors: mct/pgu - updated : 02-04-2020
|
HGNC name
| transmembrane protease, serine 2
|
HGNC id
| 11876
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in prostate carcinoma, with down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness | tumoral
| fusion
|  
|  
|  
|
with ERG, ETV1 and ETV4 in prostate cancer | tumoral
| somatic mutation
| translocation
|  
|  
|
Loss of PTEN and concomitant activation of AKTcould act in partnership with the TMPRSS2-ERG fusion protein to promote progression to prostate cancer | tumoral
| fusion
|  
|  
|  
|
TMPRSS2-ERG gene fusions were observed in 44p 100 of prostate cancer, and over 90p100 of these fusions occurred in ERG exons 3 or 4 | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| development of the TMPRSS2-ERG fusion gene is a noninvasive tumor marker for therapy assessment, risk stratification, and relapse detection to improve personalized therapy strategies for patients with prostate cancer | |
urinary TMPRSS2:ERG might become a valuable test not only for diagnosing PCa but also for distinguishing the aggressive tumors from the indolent ones | Therapy target
|
System | Type | Disorder | Pubmed |
immunology | infectious | | |
TMPRSS2-related therapeutic agents may be a promising countermeasure against the current and new outbreaks of CoVs |
| | |
| Tmprss2 plays a crucial role in viral spread within the airway of murine models infected by SARS-CoV and MERS-CoV and in the resulting immunopathology |